These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21478104)

  • 21. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
    Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
    Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
    Lyubimova NV; Churikova TK; Kushlinskii NE
    Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
    Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
    Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
    Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
    Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
    Glinicki P; Jeske W
    Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
    Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.
    Ito T; Hijioka S; Masui T; Kasajima A; Nakamoto Y; Kobayashi N; Komoto I; Hijioka M; Lee L; Igarashi H; Jensen RT; Imamura M
    J Gastroenterol; 2017 Jan; 52(1):9-18. PubMed ID: 27539256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
    Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
    Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
    J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
    Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
    Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
    PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.